 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.207.679 |
| Chemical and physical data | |
| Formula | C9H11ClN2O |
| Molar mass | 198.65 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Tebanicline (ebanicline,ABT-594) is a potent synthetic nicotinic (non-opioid) analgesic drug developed byAbbott. It was developed as a less toxicanalog of the potentpoison dart frog-derived compoundepibatidine, which is about 200 times stronger thanmorphine as ananalgesic, but produces extremely dangerous toxic side effects.[1][2] Like epibatidine, tebanicline showed potent analgesic activity againstneuropathic pain in both animal and human trials, but with far less toxicity than its parent compound.[3][4][5][6][7][8] It acts as apartial agonist at neuronalnicotinic acetylcholine receptors, binding to both theα3β4 and theα4β2subtypes.[9]
Tebanicline progressed to Phase II clinical trials in humans,[10] but was dropped from further development due to unacceptable incidence ofgastrointestinal side effects.[11] However, further research in this area is ongoing,[12][13][14][15] and the development of nicotinic acetylcholine receptor agonists is ongoing.[16][17][18][19] No agents from this class have successfully completed human clinical trials due to their unacceptable side effect profiles.
CNS Rev:[20]